142 related articles for article (PubMed ID: 32678492)
1. FOXO1 inactivation induces cisplatin resistance in bladder cancer.
Ide H; Goto T; Teramoto Y; Mizushima T; Jiang G; Nagata Y; Inoue S; Baras AS; Kashiwagi E; Miyamoto H
Cancer Sci; 2020 Sep; 111(9):3397-3400. PubMed ID: 32678492
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
3. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
4. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
Kashiwagi E; Inoue S; Mizushima T; Chen J; Ide H; Kawahara T; Reis LO; Baras AS; Netto GJ; Miyamoto H
Br J Cancer; 2018 Jan; 118(2):213-223. PubMed ID: 29123257
[TBL] [Abstract][Full Text] [Related]
6. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Chen C; Han G; Li Y; Yue Z; Wang L; Liu J
J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501
[TBL] [Abstract][Full Text] [Related]
7. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
8. MiR-1/GOLPH3/Foxo1 Signaling Pathway Regulates Proliferation of Bladder Cancer.
Liu MK; Ma T; Yu Y; Suo Y; Li K; Song SC; Zhang W
Technol Cancer Res Treat; 2019; 18():1533033819886897. PubMed ID: 31714185
[TBL] [Abstract][Full Text] [Related]
9. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
Li Y; Zu X; Hu X; Wang L; He W
Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
[TBL] [Abstract][Full Text] [Related]
10. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
11. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
12. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
13. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
15. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin.
Shiota M; Tsunoda T; Song Y; Yokomizo A; Tada Y; Oda Y; Naito S
BJU Int; 2011 Apr; 107(7):1148-53. PubMed ID: 20726978
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.
Chi HC; Chen SL; Cheng YH; Lin TK; Tsai CY; Tsai MM; Lin YH; Huang YH; Lin KH
Cell Death Dis; 2016 Aug; 7(8):e2324. PubMed ID: 27490929
[TBL] [Abstract][Full Text] [Related]
18. FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells.
Ide H; Mizushima T; Jiang G; Goto T; Nagata Y; Teramoto Y; Inoue S; Li Y; Kashiwagi E; Baras AS; Netto GJ; Kawahara T; Miyamoto H
Endocr Relat Cancer; 2020 Apr; 27(4):231-244. PubMed ID: 32031965
[TBL] [Abstract][Full Text] [Related]
19. Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44/DOX drug-resistant glioma cell line.
Chen X; Luo X; Cheng Y
Int J Mol Med; 2018 Dec; 42(6):3300-3308. PubMed ID: 30272254
[TBL] [Abstract][Full Text] [Related]
20. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
